Trypanosoma Brucei Gambiense; Infection Clinical Trial
— DiTECT-WP4Official title:
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure
Verified date | January 2021 |
Source | Institut de Recherche pour le Developpement |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study validates the diagnostic performance of cerebrospinal fluid neopterin quantification and of blood and cerebrospinal fluid trypanosomal spliced leader RNA detection for assessing outcome after treatment of human African trypanosomiasis.
Status | Completed |
Enrollment | 88 |
Est. completion date | January 31, 2021 |
Est. primary completion date | January 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 15 Years and older |
Eligibility | Inclusion Criteria: - Eligible for participation in DNDi-OXA-02-HAT clinical trial Exclusion Criteria: - Excluded for DNDi-OXA-02-HAT clinical trial; No informed consent for participation in the DiTECT-HAT-WP4 study |
Country | Name | City | State |
---|---|---|---|
Congo, The Democratic Republic of the | Programme Nationale de Lutte contre la trypanosomiase humaine Africaine | Kinshasa |
Lead Sponsor | Collaborator |
---|---|
Institut de Recherche pour le Developpement | Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo, Institute of Tropical Medicine, Belgium, Ministry of Public Health, Democratic Republic of the Congo |
Congo, The Democratic Republic of the,
González-Andrade P, Camara M, Ilboudo H, Bucheton B, Jamonneau V, Deborggraeve S. Diagnosis of trypanosomatid infections: targeting the spliced leader RNA. J Mol Diagn. 2014 Jul;16(4):400-4. doi: 10.1016/j.jmoldx.2014.02.006. Epub 2014 May 9. — View Citation
Ilboudo H, Camara O, Ravel S, Bucheton B, Lejon V, Camara M, Kaboré J, Jamonneau V, Deborggraeve S. Trypanosoma brucei gambiense Spliced Leader RNA Is a More Specific Marker for Cure of Human African Trypanosomiasis Than T. b. gambiense DNA. J Infect Dis. 2015 Dec 15;212(12):1996-8. doi: 10.1093/infdis/jiv337. Epub 2015 Jun 16. — View Citation
Tiberti N, Lejon V, Hainard A, Courtioux B, Robin X, Turck N, Kristensson K, Matovu E, Enyaru JC, Mumba Ngoyi D, Krishna S, Bisser S, Ndung'u JM, Büscher P, Sanchez JC. Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis. 2013;7(2):e2088. doi: 10.1371/journal.pntd.0002088. Epub 2013 Feb 28. — View Citation
Vincent IM, Daly R, Courtioux B, Cattanach AM, Biéler S, Ndung'u JM, Bisser S, Barrett MP. Metabolomics Identifies Multiple Candidate Biomarkers to Diagnose and Stage Human African Trypanosomiasis. PLoS Negl Trop Dis. 2016 Dec 12;10(12):e0005140. doi: 10.1371/journal.pntd.0005140. eCollection 2016 Dec. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sensitivity of SL-RNA detection in blood, SL-RNA detection in cerebrospinal fluid and of neopterin & 5-hydroxytryptophan quantification in cerebrospinal fluid for relapse after human African trypanosomiasis treatment | Index tests: qualitative detection of SL-RNA in blood, qualitative detection of SL-RNA in cerebrospinal fluid, neopterin & 5-hydroxytryptophan quantification in cerebrospinal fluid.
Reference standard: classification according to the WHO 2015 criteria as relapse or probable relapse within 18 months after treatment for human African trypanosomiasis |
18 months | |
Primary | Specificity of SL-RNA detection in blood, SL-RNA detection in cerebrospinal fluid and of neopterin & 5-hydroxytryptophan quantification in cerebrospinal fluid for cure after human African trypanosomiasis treatment | Index tests: qualitative detection of SL-RNA in blood, qualitative detection of SL-RNA in cerebrospinal fluid, neopterin & 5-hydroxytryptophan quantification in cerebrospinal fluid.
Reference standard: classification according to the WHO 2015 criteria as cure or probable cure 18 months after treatment |
18 months | |
Secondary | Sensitivity and specificity SL-RNA detection in blood for outcome assesment after treatment for human African trypanosomiasis | Index tests: qualitative detection of SL-RNA in blood post treatment day 11, month 6, month 12 and month 18.
Reference standard: Human African trypanosomiasis treatment outcome classification according to the WHO 2015 criteria |
post treatment day 11, month 6, month 12 and month 18 | |
Secondary | Sensitivity and specificity SL-RNA detection in cerebrospinal fluid for outcome assesment after treatment for human African trypanosomiasis | Index tests: qualitative detection of SL-RNA in cerebrospinal fluid at post treatment day 11, month 6, month 12 and month 18.
Reference standard: Human African trypanosomiasis treatment outcome classification according to the WHO 2015 criteria |
post treatment day 11, month 6, month 12 and month 18 | |
Secondary | Sensitivity and specificity by ROC analysis of neopterin & 5-hydroxytryptophan quantification in cerebrospinal fluid for outcome assesment after treatment for human African trypanosomiasis | Index tests: quantitative detection of neopterin & 5-hydroxytryptophan in cerebrospinal fluid at post treatment day 11, month 6, month 12 and month 18.
Reference standard: Human African trypanosomiasis treatment outcome classification according to the WHO 2015 criteria |
post treatment day 11, month 6, month 12 and month 18 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04099628 -
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
|
N/A | |
Completed |
NCT05466630 -
Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis
|
N/A | |
Recruiting |
NCT05433350 -
Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients
|
Phase 2/Phase 3 | |
Completed |
NCT05256017 -
Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
|
Phase 2/Phase 3 | |
Completed |
NCT03356665 -
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
|
N/A |